DOI: 10.25910/qg5d-6058
title: TROG 15.01 Stereotactic Prostate Adaptive Radiotherapy utilising Kilovoltage Intrafraction Monitoring (SPARK) Database

description: The data originate from the Trans-Tasman Radiation Oncology Group (TROG) 15.01 Stereotactic Prostate Adaptive Radiotherapy utilising Kilovoltage intrafraction monitoring (SPARK) clinical trial. The SPARK trial was a phase II prospective multi-institutional clinical trial approved by the Hunter New England Local Health District Human Research Ethics Committee, (HREC/15/HNE/216) and registered with clinicaltrials.gov (NCT02397317). The aim of the SPARK clinical trial was to measure the geometric and dosimetric cancer targeting accuracy achieved with a real-time image-guided radiotherapy technology named Kilovoltage Intrafraction Monitoring (KIM) for 48 prostate cancer patients treated in 5 treatment sessions. The clinical trial was performed at 5 radiotherapy centres situated in New South Wales and Victoria in Australia. During treatment, real-time tumour translational and rotational motion were determined from x-ray images using the KIM technology. Two methods were allowed to adapt to tumour motion during treatment: (1) gating by applying KIM-triggered couch shifts and (2) multi-leaf (MLC) tracking. A dose reconstruction method was used to evaluate the dose delivered to the target and organs-at-risk with and without real-time KIM monitoring. Patient reported outcomes and toxicity data were monitored up to 2 years after the completion of the treatment. The dataset contains 48 prostate cancer patient data including the planning CT images, treatment plans, RT structure sets, planned and motion-included dose volume histograms, intra-treatment kilovoltage (kV) and megavoltage (MV) projection images, tumour translational and rotational motion determined by KIM, tumour motion ground truth data determined by the triangulation method, the linear accelerator trajectory traces and patient treatment outcomes.
description: The data originate from the Trans-Tasman Radiation Oncology Group (TROG) 15.01 Stereotactic Prostate Adaptive Radiotherapy utilising Kilovoltage intrafraction monitoring (SPARK) clinical trial. In the SPARK clinical trial, 48 prostate cancer patients received 36.25 Gy dose (planning target volume D95) in 5 fractions of stereotactic body radiation therapy (SBRT) using Volumetric Modulated Arc Therapy over two arcs with treatment delivered on Varian TrueBeam, Varian Trilogy and Elekta linear accelerators at 5 radiotherapy centers in Australia. Fiducial markers were inserted into the prostate prior to treatment planning. During radiation therapy, real-time tumour translational and rotational motion were determined from x-ray images using the Kilovoltage Intrafraction Monitoring (KIM) technology. Two methods were allowed to adapt to tumour motion during treatment: gating by applying KIM-triggered couch shifts and multi-leaf (MLC) tracking. A dose reconstruction method was used to evaluate the dose delivered to the target and organs-at-risk with and without real-time KIM monitoring. Patient reported outcomes and toxicity data were monitored up to 2 years after the completion of the treatment. More details on the data structure can be found in the README file within the repository. The data anonymisation and analysis codes are available on the public Image X GitHub repository: github.com/ACRF-Image-X-Institute/SPARK-data-analysis-code.